SCHEMBL7656116

SCHEMBL7656116

O=C(O)[C@H](COc1ccccc1)NC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.45
MTNR1B P49286 3/20 0.45
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
LMNA P02545 1/20 0.42
CYP2D6 P10635 2/20 0.41
ALOX15 P16050 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
MAOA P21397 1/20 0.39
PTGS1 P23219 1/20 0.39
MME P08473 2/20 0.39
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7656123 1.00 MTNR1A (0.45) MTNR1AMTNR1BPPARGPPARALMNA
SCHEMBL16468198 0.90 ALDH1A1 (0.43) PPARGPPARA
SCHEMBL17491904 0.87 MTNR1A (0.46) MTNR1AMTNR1BLMNACYP2D6MAOA
SCHEMBL6221169 0.87 MTNR1A (0.46) MTNR1AMTNR1BLMNACYP2D6MAOA
SCHEMBL17491905 0.87 MTNR1A (0.46) MTNR1AMTNR1BLMNACYP2D6MAOA
SCHEMBL16094419 0.87 HTT (0.47) LMNAADRB2ADRB1
SCHEMBL16094416 0.87 HTT (0.47) LMNAADRB2ADRB1
SCHEMBL30854486 0.87 RXRA (0.43) CYP2D6
SCHEMBL28625906 0.87 RXRA (0.43) CYP2D6
SCHEMBL28597447 0.85 SCN9A (0.47) PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016160677-A1 COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2016-10-06 WO disclosed
US-6358978-B1 FOR THERAPY AND PROPHYLAXIS OF RHEUMATOID ARTHRITIS (IN THE CASE OF INFLAMMATION), OSTEOARTHRITIS, ASTHMA, CARDIAC INFARCT, ALZHEIMER'S DISEASE, OR ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-03-19 US disclosed